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Abstract
Introduction: Deletion or mutation of the gene encoding the cartilage extracellular matrix (ECM) protein matrilin-3
(MATN3) results in the early onset of osteoarthritis (OA), suggesting chondroprotective properties of MATN3. To
understand the mechanisms underlying these properties, we determined the effects of MATN3 protein on the
expression of several key anabolic and catabolic genes involved in chondrocyte homeostasis, and the dependence
of such regulation on the anti-inflammatory cytokine: IL-1 receptor antagonist (IL-1Ra).
Methods: The effects of recombinant human (rh) MATN3 protein were examined in C28/I2 immortalized human
chondrocytes, primary human chondrocytes (PHCs), and primary mouse chondrocytes (PMCs). Messenger RNA
levels of IL-1Ra, COL2A1, ACAN, MMP-13, and ADAMTS-4 and -5 were determined using real-time RT-PCR. Knocking
down IL-1Ra was achieved by siRNA gene silencing. IL-1Ra protein levels were quantified by ELISA and the Bio-Plex
Suspension Array System. COL2A1 protein level was quantified using Western blot analysis. Statistic analysis was
done using the two-tailed t-test or one-way ANOVA.
Results: rhMATN3 protein induced gene expression of IL-1Ra in C28/I2 cells, PHCs, and PMCs in a dose- and time-
dependent manner. Treatment of C28/I2 cells and PHCs with MATN3 protein stimulated gene expression of
COL2A1 and ACAN. Conversely, mRNA levels of COL2A1 and ACAN were decreased in MATN3 KO mice. MATN3
protein treatment inhibited IL-1b-induced MMP-13, ADAMTS-4 and ADAMTS-5 in C28/I2 cells and PHCs. Knocking
down IL-1Ra abolished the MATN3-mediated stimulation of COL2A1 and ACAN and inhibition of ADAMTS-5, but had
no effect on MATN3 inhibition of MMP-13 mRNA.
Conclusion: Our findings point to a novel regulatory role of MATN3 in cartilage homeostasis due to its capacity to
induce IL-1Ra, to upregulate gene expression of the major cartilage matrix components, and to downregulate the
expression of OA-associated matrix-degrading proteinases in chondrocytes. The chondroprotective properties of
endogenous MATN3 depend partly on its induction of IL-1Ra. Our findings raise a possibility to use rhMATN3
protein for anti-inflammatory and chondroprotective therapy.
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Introduction
Matrilin-3 (MATN3) is one of the four members of the
matrilin family of noncollagenous oligomeric ECM pro-
teins [1-4]. As the smallest member of this family, it con-
tains a single Von Willebrand Factor A (vWFA) domain,
four epidermal growth factor (EGF)-like domains, and an
alpha-helical oligomerization domain, which allows it to
form oligomers with itself or other matrilin molecules
[5]. As an extracellular matrix (ECM) protein, MATN3
was thought to play a major structural role in forming a
filamentous matrix network by interacting with collagen
fibrils, multiple proteoglycans, and other glycoproteins
[5]. Mutations in human MATN3 are associated with a
variety of skeletal diseases including multiple epiphyseal
dysplasia (MED), spondylo-epi-metaphyseal dysplasia
(SEMD), and osteoarthritis (OA) [6-9], underscoring its
importance in cartilage development and homeostasis.
Deletion of the MATN3 gene in mice results in no gross
skeletal deformity at birth; it does however, cause accel-
eration of cartilage degeneration during aging [10].
Furthermore, MATN3 gene expression is increased in
articular cartilage tissues from OA patients [11].
OA is characterized as a disregulation of cartilage
homeostasis due to excessive upregulation of catabolic
factors and the inability of the chondrocytes to ade-
quately repair the degraded matrix, resulting ultimately
in degeneration of the major cartilage ECM components
such as type II collagen fibrils and aggrecan [12-15].
ECM catabolism is largely mediated by the matrix metal-
loproteinase (MMP) family of collagenases, including
MMP-13, and by the ADAMTS family of aggrecanases
(ADAMTS-4 and -5) [14-21]. They are often expressed
in chondrocytes in response to major inflammatory cyto-
kines such as IL-1b produced by the synovium and other
joint tissues [12]. Furthermore, there is a correlation
between the increased levels of these catabolic enzymes
and inflammatory mediators such as prostaglandins,
nitric oxide (NO), and pro-inflammatory cytokines such
as IL-1b and TNF-a in synovial fluids and joint tissue.
Previous studies have implicated IL-1b as one of the
major inflammatory cytokines associated with cartilage
damage [12,22-25] due to its ability to induce or upregu-
late the expression of proteinases, including MMPs, plas-
minogen activator, and aggrecanases [25-30], and to
downregulate the expression of endogenous proteinase
inhibitors (for example, certain TIMPs) [22,31] and carti-
lage matrix components such as COL2A1 and ACAN
[32-34]. IL-1 stimulates production of pro-inflammatory
factors including prostaglandins, leukotrienes and itself
[12,35,36]. Importantly, IL-1, IL-1 receptor, and MMPs
are expressed by chondrocytes in OA cartilage and can
be immunolocalized to the same regions [37-40]. Inhibi-
tion of the IL-1b pathway presents a promising means of
preventing cartilage degradation during OA pathogenesis.
One of the major endogenous inhibitors of the IL-1 path-
way is IL-1 receptor antagonist (IL-1Ra) [41-43].
In this study we aimed to test whether MATN3 can
positively regulate cartilage homeostasis genes, including
those downstream of IL-1, in a manner that can help
explain its chondroprotective function. Here we report
for the first time several novel regulatory functions of
MATN3 including induction of IL-1Ra, stimulation of
COL2A1 and ACAN expression, and inhibition of MMP-
13 and ADAMTS-4 and -5 expression. We also tested
whether these novel regulatory properties of MATN3
depend on its induction of IL-1Ra.
Methods
MATN3 knockout animals
For the purpose of comparing Col2a1 and Acan expres-
sion between wild-type and MATN3 knockout (KO) mice
of the same C57BL/6J genetic background, mRNA was
extracted from the whole hind limbs of these mice at
embryonic day 18.5. Generation of MATN3 KO mice have
previously been described [10]. An in-frame stop codon
was introduced into the second exon of their MATN3
gene via homologous recombination during the embryonic
stem cell stage, rendering these mice functionally
MATN3-null animals. All experiments were performed
with the approval of the Rhode Island Hospital Institu-
tional Animal Care and Use Committee (IACUC, number
0231-11).
Isolation of primary chondrocytes from human and
mouse cartilage
Primary mouse chondrocytes (PMCs) were isolated from
the rib cages of 6-day-old mice. Primary human chondro-
cytes (PHCs) were isolated from normal-looking areas of
knee articular cartilage obtained from five patients under-
going total joint replacement surgery. Cartilage samples
were individually handled and processed separately to iso-
late chondrocytes. Each cartilage sample was washed twice
with sterile PBS within 2 hours of tissue collection and
diced into small fragments. Cartilage fragments were
digested in 5.0 ml of Pronase (Roche, Indianapolis, IN,
USA) in Hank’s Balanced Salt Solution (HBSS) at a con-
centration of 2.0 mg/ml for 30 minutes at 37°C under
shaking conditions. The digestion solution was removed
and cartilage was washed twice with DMEM medium (Life
Technologies, Grand Island, NY, USA). After a second
wash, DMEM was removed and replaced with 5.0 ml of
Type IA Crude Bacterial Collagenase (Sigma-Aldrich,
St. Louis, MO, USA) at 1.0 mg/ml for 8 hours at 37°C
under shaking conditions. Collagenase enzyme reaction
was stopped by adding 5.0 ml of DMEM medium contain-
ing 10% fetal bovine serum (FBS) (Life Technologies) into
the digestion mix. Solution was filtered using a 100 μm
nylon cell strainer (BD, Franklin Lakes, NJ, USA) to
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remove clumps, followed by centrifugation at 1500 rpm to
pellet the successfully isolated chondrocytes. Pellet was
washed twice with DMEM medium and cells were
counted using a hemocytometer. Finally, chondrocytes
were plated at high density (4.0 × 106 cells) in 60-mm cell
culture dishes using DMEM medium supplemented with
10% FBS and 0.2% Streptomycin (Life Technologies). All
studies involving patient tissue samples were conducted in
accordance with the Institutional Review Board (IRB) of
Rhode Island Hospital. The need to obtain patient consent
for the collection of cartilage tissue after surgery was
waived by the Rhode Island Hospital IRB.
Chondrocyte cell culture studies
Cell culture experiments were conducted using PMCs,
PHCs, and C28/I2 immortalized human chondrocytes,
and involved first plating cells in 6-well culture plates at
200,000 viable cells per well in 1:1 DMEM/F-12 media
(Life Technologies) supplemented with 10% FBS. After 48
hours, the culture medium was replaced with 2.0 ml of
serum-free 1:1 DMEM/F-12 and incubated for 5 hours
prior to treatment with recombinant human (rh) MATN3
protein (100 ng/ml or 200 ng/ml) (R&D Systems, Minnea-
polis, MN, USA) and/or rhIL-1b (5.0 ng/ml) (PeproTech,
Rocky Hill, NJ, USA) for 8 to 36 hours, unless otherwise
stated. To optimize the induction of catabolic proteases
(that is, MMP-13, ADAMTS family) by IL-1 in both pri-
mary and immortalized chondrocytes, we used serum-free
media for the duration of the treatment period as in a pre-
vious study [44].
Small interfering RNA-based silencing of IL-1Ra in PHCs
PHCs were transfected for 48 hours at approximately 40
to 50% cell confluency with a small interfering RNA
(IL1RN ON-TARGETplus siRNA) (Dharmacon, Chicago,
IL, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
The siRNA targets and suppresses the mRNA and protein
expression of all four endogenous isoforms of human
IL-1Ra. A non-silencing siRNA (Allstars Negative Control
siRNA) (Qiagen, Valencia, CA, USA) was used as control.
PHCs were plated at 200,000 viable cells per well in 6-well
culture plates 24 hours prior to siRNA transfection proce-
dure. For each well, 40 pmol of siRNA and 2.0 uL of
Lipofectamine 2000 were utilized for transfection. The
40 pmol of siRNA was first diluted in 100 uL of Opti-
MEM I Reduced Serum Media. Likewise, 2.0 uL of Lipo-
fectamine 2000 was diluted in 100 uL of Opti-MEM I
Reduced Serum Media. After 5 minutes at room tempera-
ture, the siRNA and lipid mediator solutions were gently
mixed, incubated at room temperature for 20 minutes,
and then added to cell culture wells containing 1.0 ml of
incomplete DMEM media. Cells were placed in a 37°C
incubator and media was changed after 8 hours. PHCs
were treated with MATN3 and/or IL-1b 48 hours post
transfection for subsequent cell culture experiments.
Gene expression analysis
Total RNA was isolated from PMCs, PHCs, C28/I2 cells
and the hind limbs of embryonic day 18.5 wild-type and
MATN3 KO mice on the C57BL/6J genetic background
[10] using the RNAqueous Kit (Ambion, Austin, TX,
USA) according to the manufacturer’s instructions. Gene
expression analysis was conducted by real time quantita-
tive PCR (RT-qPCR) with the DNA Engine Opticon 2
(Bio-Rad, Hercules, CA, USA) using the QuantiTect SYBR
Green PCR kit (Qiagen). For RT-qPCR, 0.5 ug of RNA
was reverse-transcribed using iScript cDNA Synthesis Kit
(Bio-Rad) according to the manufacturer’s instructions.
The cDNA of each sample was subjected to RT-qPCR
using species-specific primer pairs for genes encoding IL-
1Ra, type II collagen, aggrecan, MMP-13, and soluble (s)IL-
1Ra. Exact primer sequences can be found in Table 1.
Relative transcript levels were calculated using the delta-
delta Ct (ΔΔCt) method, normalized to rRNA 18S expres-
sion according to the following equation: X = 2 -ΔΔCt, in
which ΔΔCt = (CtExp - Ct18S) - (CtCtl - Ct18S) and X =
Relative transcript; CtCtl = Ct of control group.
Protein analysis
The Human IL-1ra/IL-1F3 Immunoassay (R&D Systems)
and the MMP-13 Human ELISA Kit (Abcam, Cambridge,
MA) were used to quantify IL-1Ra and MMP-13 protein
levels, respectively, in PHCs 24 hours following treatment
with MATN3 and/or IL-1b, according to the manufac-
turer’s instructions. PHCs were seeded at a cell density of
100,000 cells/well in 12-well cell culture plates. After
24 hours, media were changed to be serum-free and each
group was treated with MATN3 and/or IL-1b as appropri-
ate. Conditioned media were collected 24 hours later,
spun down to remove any cell debris and immediately fro-
zen down at -80°C until assays were ready to be per-
formed. The minimum detectable level of IL-1Ra and
MMP-13 by these assays were 30 pg/ml and 6.0 pg/ml,
respectively.
The Bio-Plex Suspension Array System (Bio-Rad) was
used to measure soluble IL-1Ra protein levels in cell cul-
ture medium of PHCs transiently transfected with either
an siRNA against IL-1Ra or a non-silencing scrambled
control siRNA. Transiently transfected PHCs were col-
lected 36 hours following treatment with MATN3 and/or
IL-1b. These samples were analyzed using Bio-Plex Pro
Human Cytokine Assay in duplicate per each biological
replicate (two per treatment group) according to the
manufacturer’s instructions. Protein quantification of
type II collagen was conducted via western blot analysis
Jayasuriya et al. Arthritis Research & Therapy 2012, 14:R197
http://arthritis-research.com/content/14/5/R197
Page 3 of 13
using standard protocols. Prior to Western blot analysis
of type II collagen protein, primary human chondrocytes
transfected with either the IL-1Ra-silencing siRNA or the
non-silencing scrambled control siRNA, were seeded and
cultured for 48 hours in DMEM containing 10% FBS in
the presence and absence of rhMATN3 (200 ng/ml) and/
or IL-1b (5.0 ng/ml). Cell culture pellets were resus-
pended in 50 uL of RIPA buffer (Cell Signaling Technol-
ogy, Boston, MA, USA) containing protease inhibitors.
Protein concentrations were determined using a Bradford
Assay (Bio-Rad), according to the manufacturer’s instruc-
tions, and a NanoDrop 2000c (Thermo Fisher Scientific,
Rockford, IL, USA). Western blot analysis was performed
using standard protocols. A previously characterized
mAb against collagen II [45,46] (NeoMarkers, Fremont,
CA, USA) was used as the primary antibody. Beta-actin
was used as a loading control for normalization. Imaging
was done using the Odyssey Infrared Imager (LI-COR
Biosciences, Lincoln, NE, USA). Western band intensities
were quantified using ImageJ software program (NIH,
Bethesda, MD, USA).
Statistical analysis
Mean values were calculated and are presented with error
bars representing ± SDM (one standard deviation of the
mean). Two-tailed t-tests were used to analyze data repre-
sented in Figure 1B and 2D. For all else, statistical analysis
was done using one-way analysis of variance (ANOVA)
followed by post hoc test analysis. Statistical significance
was accepted at P < 0.05 for all analyses.
Results
MATN3 induces gene expression of IL-1Ra
IL-1Ra is a potent endogenous inhibitor of the IL-1
pathway [37,38]. To determine whether MATN3 affects
IL-1Ra synthesis, we treated immortalized human C28/
I2 chondrocytes with rhMATN3 protein. MATN3
induced mRNA expression of IL-1Ra in a dose-
dependent manner (Figure 1A). We also observed an
increase of IL-1Ra mRNA levels in PMCs treated with
rhMATN3 protein (Figure 1B). RhMATN3 protein
induced IL-1Ra mRNA in PHCs in the presence or
absence of IL-1b (Figure 1C). Treating PHCs with
MATN3 in the presence of IL-1b significantly enhanced
IL-1Ra protein concentration in culture medium
compared to that of cells treated with IL-1b alone
(Figure 1D). The kinetics of IL-1Ra mRNA induction by
MATN3 in C28/I2 cells and PHCs was also analyzed
(see Additional file 1). The induction of IL-1Ra mRNA
persisted during a 24-hour treatment period with more
pronounced induction in the shorter incubation period.
Thus, MATN3 induces the mRNA and protein expres-
sion of IL-1Ra in chondrocytes.
MATN3 stimulates expression of COL2A1 and ACAN
To investigate whether MATN3 stimulates type II col-
lagen gene (COL2A1) expression in chondrocytes, we
treated C28/I2 cells (Figure 2A) and PHCs (Figure 2B)
with rhMATN3 protein for 8 hours. We observed a sig-
nificant induction of COL2A1 expression in these chon-
drocytes. MATN3 induction of COL2A1 was also
observed after 24 hours treatment (see Additional file 2).
While treatment with IL-1b significantly decreased
COL2A1 mRNA levels in both C28/I2 cells and PHCs,
treatment with MATN3 at the same time reversed this
decrease (Figure 2A,B). MATN3 treatment also increased
aggrecan gene (ACAN) expression by PHCs in the pre-
sence of IL-1b (Figure 2C).
To determine whether the lack of MATN3 affects the
expression of COL2A1 and ACAN in chondrocytes, we
analyzed RNA isolated from the limbs of MATN3 KO
and wild-type mice. The MATN3 KO mice exhibited 50%
reduction of Col2a1 and Acan mRNA levels compared to
their wild-type littermates (Figure 2D) indicating that the
absence of MATN3 suppresses the expression of these
two genes.
Table 1 Forward and reverse primer sequences used for real-time PCR
Species Gene Forward sequence Reverse sequence
Human ADAMTS-4 5’-CCCCAGACCCCGAAGAGCCA-3’ 5’-CCCGCTGCCAGGCACAGAAG-3’
Human ADAMTS-5 5’-GGCCGTGGTGAAGGTGGTGG-3’ 5’-GCTGCGTGGAGGCCATCGTC-3’
Human ACAN 5’-ACCAGACGGGCCTCCCAGAC-3’ 5’-TGGCTCTGCCCCAGAGGGAC-3’
Human COL21A 5’-TGAGGGCGCGGTAGAGACCC-3’ 5’-TGCACACAGCTGCCAGCCTC-3’
Human IL-1Ra (pair 1)* 5’-CCCGTGAAGGAGAGCCCTTCATTTG-3’ 5’-ACTTTCACCATCATTTCACAAATGCAG-3’
Human IL-1Ra (pair 2)** 5’-TGTTCCATTCAGAGACGATCTGCCG-3’ 5’-GAGCATGAGGCTCAATGGGTACC-3’
Human MMP-13 5’-ATGCGGGGTTCCTGATGTGG-3’ 5’-GGCCCAGGAGGAAAAGCATG-3’
Murine Acan 5’-CAGTGCGATGCAGGCTGGCT-3’ 5’-CCTCCGGCACTCGTTGGCTG-3’
Murine Col2a1 5’-CACACTGGTAAGTGGGGCAAGACCG-3’ 5’-GGATTGTGTTGTTTCAGGGTTCGGG-3’
Murine IL-1Ra 5’-ACCCATGGCTTCAGAGGCAGC-3’ 5’-GCCCCCGTGGATGCCCAAG-3’
*Primer pair used for IL-1Ra expression analysis in C28/I2 immortalized human chondrocytes and primary human chondrocytes for Figure 1A, 1C and Additional
file 1. **Primer pair used for IL-1Ra expression analysis in primary human chondrocytes for Figure 4A and 4B. ACAN, aggrecan; COL2A1, type II collagen; IL-1Ra,
interleukin-1 receptor antagonist; MMP-13, matrix metalloproteinase-13.
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MATN3 inhibits gene expression of MMP-13, ADAMTS-4
and ADAMTS-5
We next examined whether MATN3 could inhibit the
expression of IL-1b-induced protease genes. In C28/I2
cells, IL-1b treatment increased MMP-13 mRNA levels
and MATN3 treatment decreased MMP-13 expression in
both the presence and absence of IL-1b (Figure 3A). IL-
1b treatment also increased MMP-13 gene expression by
PHCs and elevated MMP-13 mRNA levels and protein
concentrations in PHC-conditioned media while treat-
ment with MATN3 abrogated this increase significantly
(Figure 3B, C). Likewise, the IL-1b-induced ADAMTS-4
and -5 gene expression was inhibited by MATN3 in C28/
I2 cells (Figure 3D), and in PHCs (Figure 3E).
IL-1Ra mRNA and soluble protein levels are diminished
by IL1Ra siRNA
Previous studies have shown that IL-1Ra antagonizes
IL-1b stimulation of catabolic gene expression and its
inhibition of anabolic gene expression. We hypothesize
that the chondroprotective properties of MATN3 are
dependent on its upregulation of IL-1Ra. To test
whether MATN3 acts through IL-1Ra to regulate the
expression of anabolic and OA-associated catabolic
genes, we first knocked down all isoforms of IL-1Ra
using a small interfering RNA (siRNA). Since the endo-
genous soluble IL-1Ra protein levels present in C28/I2
cell supernatants were too low to accurately quantify, all
knock-down experiments were conducted in PHCs. The
siRNA transfection successfully knocked down both
IL-1Ra mRNA (Figure 4A, B) and protein expression
(Figure 4C) in PHCs, both in the presence and absence
of IL-1b.
MATN3 stimulation of COL2A1 and ACAN depends on
IL-1Ra
We then determined the effect of MATN3 on COL2A1
expression in IL-1Ra knocked-down PHCs. In the control
Figure 1 Matrilin-3 MATN3) enhances IL-1Ra expression by chondrocytes. Recombinant human (rh) MATN3 protein enhances the gene
expression of IL-1Ra in a dose-dependent manner at 12 hours post cell culture treatment as seen here in C28/I2 cells (A). Recombinant MATN3
also enhances IL-1Ra expression in primary mouse chondrocytes after 24 hours of treatment (B). MATN3-induced IL-1Ra gene expression is
evident in primary human chondrocytes (PHCs) at 24 hours post treatment in both the presence and absence of IL-1b (C). PHCs treated with
both MATN3 and IL-1b for 24 hours exhibit significantly higher concentrations of IL-1Ra protein in their cell media, relative to the media of cells
treated with IL-1b alone (D). In these experiments, rh MATN3 protein is used at one of two concentrations: lower dose (+) of 100 ng/ml, or
higher dose (++) of 200 ng/ml. Rh IL-1b protein treatment is always 5.0 ng/ml. *Significant differences (P ≤ 0.05) from the untreated control
group; #significant differences (P ≤ 0.05) from the IL-1b only treated group. Data are representative of three individual experiments.
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cells, which were transfected with a scrambled siRNA
construct, MATN3 treatment rescued the IL-1b induced
downregulation of COL2A1 mRNA (Figure 5A, left).
COL2A1 protein levels were also enhanced by MATN3
treatment in both the absence and presence of IL-1b
(Figure 5B). In contrast, MATN3 was incapable of enhan-
cing COL2A1 mRNA (Figure 5A, right) or protein levels
(Figure 5B) in cells transfected with the IL-1Ra siRNA.
Similarly, MATN3 reduced the extent of IL-1b-induced
downregulation of ACAN mRNA expression in cells
transfected with the scrambled siRNA construct (Figure
5C, left) but not in cells transfected with the IL-1Ra
siRNA (Figure 5C, right).
MATN3 inhibition of ADAMTS-5, but not of MMP-13,
depends on IL-1Ra
To test whether MATN3 inhibition of matrix proteases is
dependent on IL-1Ra, we quantified their expression
levels in the IL-1Ra knock-down chondrocytes. Knocking
down IL-1Ra chondrocytes significantly increased the
basal level of ADAMTS-5 expression (Figure 6A, compare
conditions in the absence of MATN3 or IL-1b). The pre-
sence of MATN3 significantly inhibited the upregulation
of ADAMTS-5 by IL-1b (Figure 6A, left panel, P ≤ 0.05).
However, this inhibition was not significant in IL-1Ra
knock-down chondrocytes (Figure 6A, right panel, P =
0.37). Thus MATN3 inhibition of ADAMTS-5 is at least
Figure 2 Matrilin-3 (MATN3) maintains the expression of key cartilage extracellular matrix (ECM) genes. Recombinant human (rh) MATN3
treatment maintains type II collagen (COL2A1) gene expression in the presence and absence of IL-1b in C28/I2 cells (A) and primary human
chondrocytes (PHCs) (B) at 8 hours. MATN3 also inhibits the IL-1b-induced downregulation of aggrecan (ACAN) gene expression in PHCs at 36
hours (C). Whole limb mRNA analysis of newborn MATN3 knockout (KO) mice of the C57BL/6J background reveal lower basal gene expression of
Col21a and Acan compared to wild-type mice of the same genetic background (D). For all cell culture experiments, rh MATN3 protein is used at
200 ng/ml. Rh IL-1b protein treatment is always 5.0 ng/ml. *Significant differences (P ≤ 0.05) from the untreated control group; #significant
differences (P ≤ 0.05) from the IL-1b only treated group. For cell culture experiments, data are representative of three individual experiments (n =
5 for mouse whole limb mRNA studies).
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partly dependent on IL-1Ra. In contrast, knocking down
IL-1Ra did not increase the basal level of MMP-13 gene
expression (Figure 6B). In addition, MATN3 inhibition of
MMP-13 gene expression was significant in both control
and IL-1Ra knock-down cells suggesting that MATN3
inhibition of MMP-13 is not mediated by IL-1Ra.
Discussion
Mutations in human MATN3 are associated with a vari-
ety of human cartilage degenerative diseases including
chondrodysplasia and OA [6-9]. These genetic studies
strongly suggest that the normal MATN3 gene product
is chondroprotective. Since MATN3 protein is an ECM
protein, an accepted hypothesis is that its chondropro-
tective activity is due to its structural properties, which
may help to maintain tissue integrity [47]. In this study
however, we hypothesized that MATN3 may also be
capable of preventing the IL-1b-induced disregulation of
cartilage homeostasis genes thereby preventing the hall-
mark of OA development.
Here we demonstrated that rhMATN3 protein induces
gene expression of IL-1Ra in three chondrocyte culture
models: immortalized human C28/I2 chondrocytes, PHCs
and PMCs. MATN3 increased IL-1Ra mRNA production
in the presence and absence of the inflammatory cytokine
IL-1b in a dose- and time-dependent manner. Further-
more, MATN3 treatment increased the soluble IL-1Ra
protein levels in the presence of IL-1b in chondrocytes, as
determined by ELISA and Bio-Plex Array analysis.
IL-1Ra, an IL-1a/b protein mimic, is a major endogen-
ous inhibitor of the IL-1b pathway [12,41-43]. It binds
IL-1R1, thereby preventing IL-1 downstream signaling. IL-
1Ra is potentially chondroprotective, since it inhibits IL-
1b, which is a major stress and inflammation cytokine that
is closely associated with OA pathogenesis. The concen-
tration of soluble IL-1Ra decreases with increasing grades
Figure 3 Matrilin-3 MATN3) inhibits the expression of several osteoarthritis (OA)-associated proteases. Recombinant human (rh) MATN3
protein inhibits the gene expression of metalloproteinase (MMP)-13 in a dose-dependent manner in the presence and absence of IL-1b in C28/
I2 cells (A). MATN3 inhibits IL-1b-induced MMP-13 mRNA levels (B) and protein levels in primary human chondrocyte (PHC)-conditioned media
(C). MATN3 inhibits the mRNA expression of OA-associated proteases ADAMTS-4 and ADAMTS-5 in C28/I2 cells (D) and PHCs (E). MMP-13 mRNA
and protein analysis were conducted after MATN3 treatment for 24 hours. In these experiments, rh MATN3 protein is used at one of two
concentrations: lower dose (+) of 100 ng/ml, or higher dose (++) of 200 ng/ml. Rh IL-1b protein treatment is always 5.0 ng/ml. *P ≤ 0.05, **P ≤
0.01, for statistically significant differences from the untreated control group; #P ≤ 0.05, ##P ≤ 0.01 for statistically significant differences from the
IL-1b only treated group. Data are representative of three individual experiments.
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of articular chondral damage in human patients [48].
Knocking down IL-1Ra results in the early onset of arthri-
tis in multiple mouse genetic backgrounds. IL-1Ra KO
mice bred in both BALB/cA and MFIx129 backgrounds
developed severe inflammatory arthritis [49]. Conversely,
in vivo IL-1Ra gene transfer reduces surgically induced
OA severity in rabbits [50]. The level of IL-1Ra present in
the rabbit synovium positively correlated with the reduc-
tion in articular cartilage lesions.
Because of its chondroprotective properties, it is of
paramount importance to study how IL-1Ra gene
expression is regulated. IL-1Ra is produced by many cell
types including chondrocytes [51]. It is important to
recognize that the chondroprotective effects of IL-1Ra
in OA are only observable when the protein is consis-
tently present in the arthritic joint. This explains why
short-lived drugs based on IL-1Ra (that is, AnikinRA)
[52], which only last a few hours post-intra-articular
injection into human patients, have limited efficacy in
OA treatment [53]. Thus, finding a means of continu-
ously stimulating autologous IL-1Ra production in
chondrocytes may provide an effective alternative for
sustaining articular cartilage integrity by dampening
inflammation under arthritic conditions. We show here
Figure 4 Small interfering RNA significantly suppresses mRNA and protein levels of IL-1Ra. Knocking down all isoforms of IL-1Ra via
IL1RN siRNA treatment reduces the IL-1b induction of this gene as observed at two time points (24, 36 hours) post cell culture treatment (A, B).
This also results in significant reduction of soluble IL-1Ra protein levels in primary human chondrocyte (PHC) cell supernatants after 24 hours (C).
PHCs treated with a nonspecific scrambled siRNA construct is used as the control group. For these experiments, recombinant human (rh)
matrilin-3 (MATN3) protein is used at 200 ng/ml. Rh IL-1b protein treatment is always 5.0 ng/ml. *P ≤ 0.05 for statistically significant differences
between groups. Data are representative of three individual experiments.
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for the first time that MATN3 protein is capable of sti-
mulating IL-1Ra expression in chondrocytes. Our find-
ings may also explain a previous report of increased
MATN3 expression in OA patients [11], since articular
chondrocytes may be attempting to inhibit IL-1-induced
joint tissue destruction by increasing MATN3 produc-
tion as a means of recovery.
To further test the hypothesis that MATN3 is chondro-
protective, we examined the effect of MATN3 on the
expression of anabolic genes such as COL2A1 and ACAN
and catabolic genes such as ADAMTS-4 and -5 and
MMP-13 in chondrocytes. Recombinant human MATN3
protein enhanced COL2A1 expression while inhibiting
the IL-1b-induced downregulation of COL2A1 and
Figure 5 Matrilin-3 MATN3) regulation of type II collagen (COL2A1) and aggrecan (ACAN) gene expression, as well as COL2A1 protein
expression requires IL-1Ra. Knocking down IL-1Ra abolishes the ability of recombinant human (rh) MATN3 protein to maintain COL2A1 gene
expression in primary human chondrocytes (PHCs) that are challenged with IL-1b (A). A significant reduction in the basal gene expression of
COL2A1 is also observed in IL-1Ra knock-down PHCs. PHCs cultured for 48 hours in media supplemented with rh MATN3 protein (200 ng/ml)
exhibit increased COL2A1 protein levels; however, upon suppressing IL-1Ra via siRNA-based gene knock-down, MATN3 enhancement of collagen
is diminished according to western blot analysis (B). Relative quantification of band intensity is the accumulated result of three individual
experiments (n = 3). Knocking down of IL-1Ra also abolishes MATN3 stimulation of ACAN gene expression (C). The concentration of rh MATN3
protein used was 200 ng/ml and of IL-1b was 5.0 ng/ml for all experiments. (A, C) Gene expression analysis was conducted 36 hours post
exposure to cell culture treatment conditions. #P ≤ 0.05 for statistically significant differences from the untreated group; *P ≤ 0.05 for statistically
significant differences between groups. (B) *P ≤ 0.05 for statistically significant differences from the untreated control group. Individual
experiments were done in biological triplicate per patient sample. Data are representative of five individual experiments.
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ACAN. Conversely, the lack of MATN3 resulted in
reduced basal expression of these chondrogenic genes in
MATN3 KO mice in comparison to wild-type mice of the
same genetic background. The levels of both Col2a1 and
Acan were reduced by approximately 50% compared to
wild-type mice. Thus, MATN3 is necessary to maintain
normal expression of these genes in cartilage. It is inter-
esting that MATN3 KO mice have relatively normal ske-
letal development [10] despite reduced levels of Col2a1
and Acan as observed here for the first time. This is con-
sistent with the finding that Col2a1and Acanheterozy-
gous KO mice have normal skeletal development at birth
[54,55]. However, our data also show that, while IL-1b
treatment greatly reduces the levels of COL2A1 and
ACAN in chondrocytes, the presence of MATN3 inhibits
this further reduction of matrix synthesis by IL-1b. Since
the IL-1b levels are often elevated in OA, the lack of
MATN3 may result in a more severe phenotype during
skeletal aging than during development. Thus, this newly
discovered MATN3 property of inhibiting IL-1b may
explain why the lack of MATN3 results in accelerated
OA during aging despite relatively normal skeletal devel-
opment in MATN3 KO mice [10].
MATN3 protein not only maintained expression of
anabolic genes including COL2A1 and ACAN in our
experiments, but also inhibited expression of catabolic
genes induced by IL-1b, including MMP-13, ADAMTS-4
and -5. This inhibitory effect correlated with the concen-
tration of MATN3 protein in the culture medium. These
catabolic genes are closely related to OA pathogenesis
with increased gene expression and/or activity [12]. The
lack of the ADAMTS-5 gene also protects cartilage
degeneration from abnormal mechanical loading in the
mouse joint [20]. Thus, inhibiting gene expression of
these OA-associated matrix proteases induced by IL-1b
may also contribute to the chondroprotective properties
of MATN3.
Since MATN3 induces IL-1Ra expression and inhibits
the effects of IL-1b in chondrocytes, we determined
whether these two events are dependent. Knocking down
IL-1Ra using siRNA abolished both IL-1Ra mRNA and
protein levels in chondrocytes. This was also confirmed by
the failure of IL-1b treatment to induce IL-1Ra expression
in the IL-1Ra knocked-down chondrocytes. The levels of
COL2A1 and ACAN mRNA levels were significantly lower
in these IL-1Ra knocked-down chondrocytes compared to
wild-type chondrocytes. Furthermore, treatment with
MATN3 protein failed to significantly enhance COL2A1
and ACAN mRNA levels in the presence of IL-1b. Simi-
larly, western blot analysis indicated that silencing IL-1Ra
resulted in an overall reduction of COL2A1 protein level.
Silencing IL-1Ra also completely abolished MATN3
induction of COL2A1 protein level, both in the absence
and presence of IL-1b. This suggests that the ability of
MATN3 to maintain anabolic markers such as COL2A1
and ACAN in chondrocytes depends on the presence of
IL-1Ra.
Our study reveals that MATN3 inhibition of IL-1b-sti-
mulated expression of catabolic proteases is mediated by
both IL-1Ra-dependent and -independent pathways. In
the IL-1Ra knocked-down cells, ADAMTS-5 mRNA
levels were significantly increased in comparison to wild-
type chondrocytes, while MMP-13 mRNA levels
remained unchanged. Upon IL-1b treatment, MATN3
inhibition of the stimulation of ADAMTS-5 in IL-1Ra
knocked-down chondrocytes became statistically insignif-
icant. In contrast, MATN3 still significantly inhibited the
stimulation of MMP-13 by IL-1b in the knocked-down
Figure 6 Matrilin-3 MATN3) inhibition of ADAMTS-5 gene expression require IL-1Ra. Knocking down IL-1Ra in primary human
chondrocytes (PHCs) only partially affects MATN3-induced inhibition of ADAMTS-5 (A) and does not seem to significantly affect MMP-13 gene
expression (B). The concentration of recombinant human MATN3 protein used was 200 ng/ml and of IL-1b was 5.0 ng/ml. Gene expression
analysis was conducted 36 hours post exposure to cell culture treatment conditions. #P ≤ 0.05 for statistically significant differences from the
untreated group; *P ≤ 0.05 for statistically significant differences between groups. Individual experiments were done in biological triplicate per
patient sample. Data are representative of five individual experiments.
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cells as in wild-type chondrocytes. The same was true for
ADAMTS-4 gene expression as well (not shown). This
indicates that MATN3 inhibition of IL-1b upregulation
of ADAMTS-5 is IL-1Ra-dependent, while its inhibition
of IL-1b upregulation of MMP-13 and ADAMTS-4 is not.
In addition to IL-1Ra, there are other antagonists in the
IL-1b signaling pathway including a decoy receptor
IL-1RII, an inhibitory receptor SIGIRR, and a soluble
receptor sIL-1RAcP [56,57]. MATN3 may inhibit IL-1b-
stimulation of MMP-13 by upregulating one of these
antagonists. Alternatively, MATN3 may also exert its reg-
ulatory function by downregulating agonists in the IL-1
signaling pathway that are independent of IL-1Ra. A lim-
itation of this study involves the use of a relatively small
patient pool (total of three to five patients) for the acqui-
sition of primary human chondrocytes. The conclusion
of MATN3 induction of IL-1Ra is, however, valid in
chondrocytes from each patient. Thus, experiments
involving the use of primary human chondrocyte cultures
accomplished its intended purpose of corroborating the
findings observed in the C28/I2 human chondrocyte cell
line.
The mechanism by which MATN3 regulates IL-1Ra is
currently unknown. Given that IL-1Ra mRNA transcript
levels are elevated relatively quickly (within 24 hours of
exposure to MATN3 recombinant protein), the stimula-
tion by MATN3 of this anti-inflammatory cytokine may
be a direct effect. Cartilage extracellular matrix molecules
such as hyaluronan have previously been shown to med-
iate regulatory functions by direct interaction with cell
surface molecules and/or receptors [58,59]. It is possible
that chondrocytes have an endogenous receptor through
which MATN3 signals to mediate its regulatory function
(s). It has been shown previously that matrilins may inter-
act with integrins or other plasma membrane receptors in
chondrocytes [60]. It remains to be determined whether
the regulatory functions of MATN3, as shown here, are
mediated by these receptors.
We have shown that MATN3 treatment inhibits OA-
associated catabolic gene expression. Interestingly, a
previous study has shown that treatment of human
chondrocytes with very high concentrations of murine
recombinant MATN3 protein leads to activation of OA-
associated catabolic genes [61]. It is important to note
that there are two clear differences between the afore-
mentioned study and this one. The first is that, while
mouse recombinant MATN3 was used to treat PHCs in
the previous study, we used human recombinant
MATN3 to treat human cells in this study. The second,
and perhaps a major difference, is the concentration of
recombinant MATN3 used to treat chondrocytes.
Recombinant MATN3 protein was used at 5 to 50 μg/ml
concentrations in the previous study, which is 50 to 500
times higher than the concentrations (100 to 200 ng/ml)
used in this study. Proteins at concentrations significantly
higher than the physiological levels may exert toxic
effects on cells thereby triggering production of degen-
erative proteases. Indeed, chondrocytes treated with type
II collagen at the same high concentrations also induced
matrix protease expression in the previous study [61].
Thus, the data from the two studies indicate that
MATN3 is chondroprotective at the 100 to 200 ng/ml
concentration range, while stimulating catabolic path-
ways at the 5 to 50 μg/ml concentration range, which
may reflect supra-physiological levels.
Conclusion
This study presents evidence of several novel regulatory
functions of MATN3, including induction of IL-1Ra
expression, maintenance of collagen II and aggrecan gene
expression, and inhibition of the IL-1b-induced gene
expression of certain catabolic matrix proteases including
ADAMTS-5. These regulatory functions are MATN3
concentration-dependent. We further demonstrate that
some of these regulatory functions (that is, enhancement
of COL2A1 and ACAN gene expression) are dependent
on IL-1Ra, while other regulatory functions are indepen-
dent (that is, inhibition of IL-1b-induced MMP-13 gene
expression). These observations were made in multiple
chondrocyte culture models, including primary and
immortalized cells, and human and mouse species. It
provides a novel mechanism for chondroprotective prop-
erties of MATN3, which has been strongly indicated by
previous genetic studies in humans and mice. It suggests
that MATN3 plays not only a structural role in cartilage
ECM, but also a regulatory role in cartilage homeostasis
by modulating genes critical for matrix synthesis, degra-
dation, and inflammation. It also raises an intriguing pos-
sibility of using MATN3, a cartilage matrix protein, for
stimulating endogenous anti-inflammatory and chondro-
protective properties in cartilage.
Additional material
Additional file 1: Kinetics of matrilin-3 (MATN3)-induced IL-1Ra
gene expression in human chondrocytes. A figure showing MATN3
stimulation of IL-1Ra gene upregulation by C28/I2 cells and primary
human chondrocytes (PHCs) in the absence (A, C) and presence of IL-1b
(B, D). Cells were treated with 0, 100 or 200 ng/ml of recombinant
human MATN3 protein. IL-1b was used at a concentration of 5.0 ng/ml.
*P ≤ 0.05 for statistically significant differences relative to the 0 ng/ml
treatment group, for each respective time point. Individual experiments
were done in biological triplicate.
Additional file 2: Matrilin-3 (MATN3) stimulates type II collagen
(COL2A1) mRNA levels for at least 24 hours in human chondrocytes.
A figure showing that MATN3 induces COL2A1 mRNA levels in C28/I2
cells (A) and primary human chondrocytes (PHCs) (B) after 24 hours
treatment. Recombinant human (rh) MATN3 protein is used at 200 ng/ml
and rh IL-1b protein treatment is used at 5.0 ng/ml. *P ≤ 0.05 for
statistically significant differences from the untreated control group;
Jayasuriya et al. Arthritis Research & Therapy 2012, 14:R197
http://arthritis-research.com/content/14/5/R197
Page 11 of 13
#P ≤ 0.05 for statistically significant differences from the IL-1b only
treated group. Data are representative of three individual experiments.
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